217 related articles for article (PubMed ID: 22950441)
1. Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
May CH; Lincoff AM
Expert Opin Drug Saf; 2012 Nov; 11(6):959-67. PubMed ID: 22950441
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
Anderson SD; Shah NK; Yim J; Epstein BJ
Ann Pharmacother; 2010 Mar; 44(3):524-37. PubMed ID: 20124464
[TBL] [Abstract][Full Text] [Related]
3. Review of ticagrelor in the management of acute coronary syndromes.
Burgess S; Mallard TA; Juergens CP
Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1315-25. PubMed ID: 22924796
[TBL] [Abstract][Full Text] [Related]
4. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
5. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
Storey RF; Becker RC; Harrington RA; Husted S; James SK; Cools F; Steg PG; Khurmi NS; Emanuelsson H; Cooper A; Cairns R; Cannon CP; Wallentin L
Eur Heart J; 2011 Dec; 32(23):2945-53. PubMed ID: 21804104
[TBL] [Abstract][Full Text] [Related]
6. Ticagrelor: a novel reversible oral antiplatelet agent.
Nawarskas JJ; Clark SM
Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
[TBL] [Abstract][Full Text] [Related]
7. Ticagrelor: a review of its use in adults with acute coronary syndromes.
Dhillon S
Am J Cardiovasc Drugs; 2015 Feb; 15(1):51-68. PubMed ID: 25672642
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L;
Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347
[TBL] [Abstract][Full Text] [Related]
9. Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
Cheng JW
Clin Ther; 2012 Jun; 34(6):1209-20. PubMed ID: 22521881
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
Husted S
Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
[TBL] [Abstract][Full Text] [Related]
11. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Becker RC; Bassand JP; Budaj A; Wojdyla DM; James SK; Cornel JH; French J; Held C; Horrow J; Husted S; Lopez-Sendon J; Lassila R; Mahaffey KW; Storey RF; Harrington RA; Wallentin L
Eur Heart J; 2011 Dec; 32(23):2933-44. PubMed ID: 22090660
[TBL] [Abstract][Full Text] [Related]
12. P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome.
Crouch MA; Colucci VJ; Howard PA; Spinler SA
Ann Pharmacother; 2011 Sep; 45(9):1151-6. PubMed ID: 21852599
[TBL] [Abstract][Full Text] [Related]
13. Ticagrelor. Acute coronary syndromes: nothing new.
Prescrire Int; 2011 Oct; 20(120):229-33. PubMed ID: 21970081
[TBL] [Abstract][Full Text] [Related]
14. Emerging oral antiplatelet therapies for acute coronary syndromes.
Pollack CV
Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor: the first novel reversible P2Y(12) inhibitor.
Htun WW; Steinhubl SR
Expert Opin Pharmacother; 2013 Feb; 14(2):237-45. PubMed ID: 23268703
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor: positive, negative and misunderstood properties as a new antiplatelet agent.
Steiner JB; Wu Z; Ren J
Clin Exp Pharmacol Physiol; 2013 Jul; 40(7):398-403. PubMed ID: 23590223
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
James S; Budaj A; Aylward P; Buck KK; Cannon CP; Cornel JH; Harrington RA; Horrow J; Katus H; Keltai M; Lewis BS; Parikh K; Storey RF; Szummer K; Wojdyla D; Wallentin L
Circulation; 2010 Sep; 122(11):1056-67. PubMed ID: 20805430
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive comparative review of adenosine diphosphate receptor antagonists.
Oh EY; Abraham T; Saad N; Rapp JH; Vastey FL; Balmir E
Expert Opin Pharmacother; 2012 Feb; 13(2):175-91. PubMed ID: 22216937
[TBL] [Abstract][Full Text] [Related]
19. Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes.
Doggrell SA
IDrugs; 2009 May; 12(5):309-17. PubMed ID: 19431096
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Wijeyeratne YD; Joshi R; Heptinstall S
Expert Rev Clin Pharmacol; 2012 May; 5(3):257-69. PubMed ID: 22697589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
